Emmes has formed a strong ophthalmic network through long-standing relationships with many retina clinical trial sites and investigators. This decreases study start time and allows for participants to receive potential therapeutics on an abbreviated timeline
AI promises to expand access to health care and make disease screening and diagnosis using Machine Learning (ML) and AI more affordable. Featured Clinical Studies: 1. Emmes continues to serve as the full services provider for pivotal studies of AI...
When the US Food and Drug Administration (FDA) put a clinical hold on further development of an intravitreal gene therapy, it was a serious setback not only for the Sponsor, but for hopeful patients as well. An independent Data Monitoring Committee...
Emmes has served for 25 years as the Statistical and Data Coordinating Center (SDCC) for the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (NIAID-DMID)’s extramural research program....
Emmes is known for excellence in clinical trial support, that stem from our roots in statistical science and unwavering dedication to delivering superior research support as a CRO since 1977. With the COVID-19 pandemic beginning February 2020, the...
A single cloud-based platform solution system can improve the speed of set up and data collection with the flexibility of a configurable system and enhances data quality and speeds study times. Sponsors are looking for needed technology combined...